Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 1, 2008, Pages 53-62

  Shlay, Judith C ^a,e   Sharma, Shweta ^b   Peng, Grace ^b   Gibert, Cynthia L ^c   Grunfeld, Carl ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DENVER PUBLIC HEALTH   (United States)

Author keywords

Adverse effects; Body composition; HIV; Lipodystrophy; Nucleoside reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABDOMEN; ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; SKINFOLD; THIGH; TRICEPS BRACHII MUSCLE;

ADULT; COHORT STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; SUBCUTANEOUS FAT; ZIDOVUDINE;

EID: 42649097250     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816856ed     Document Type: Article

References (44)

1. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215.
2. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
3. Bogner JR, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
4. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluation by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPCO study. AIDS. 2000;14:37-49.
5. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50-55.
6. Mallon PWG, Miller J, Cooper D, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979.
7. Mallal SA, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
8. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-2454.
9. Lichtenstein KA, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.
10. Shlay J, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine versus abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
11. Bacchettti P, Gripshoever B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131.
12. Study of Fat Redistribution and Metabolic Change in HIV Infection. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-571.
13. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
14. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
15. Dube M, Parker R, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
16. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2006;44:139-147.
17. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS. 2004;18:1029-1036.
18. Moyle G, Baldwin B, Landroudi B, et al. A 48-week, randomized, open-label comparison of 3 abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
19. Tien P, Schneider M, Cole S, et al. Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr. 2007;44:43-48.
20. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004;18:1475-1478.
21. Tien P, Cole S, Williams C, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2003;35:461-466.
22. Mulligan K, Parker R, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41:590-597.
23. MacArthur R, Chen L, Mayer D, et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 2001;22:139-141.
24. MacArthur R, Novak R, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): a long-term randomised trial. Lancet. 2006;368:2125-2135.
25. Shlay J, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral-naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44:506-517.
26. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mort Wkly Rep. 1992;41(RR-17):1-19.
27. Wang J, Bartsch G, Raghavan S, et al. Reliability of body composition and skinfold measurements by observers trained in groups. International Journal of Body Composition Research. 2004;2:31-36.
28. Lohman TG, Roche A, Martorell R. Anthropometric Standard Reference Manual. Champaign, IL: Human Kinetics; 1988.
29. Wang J, Thorton J, Kolesnik S, et al. Anthropometry in body composition: an overview. Ann N Y Acad Sci. 2000;904:317-326.
30. Laird NM, Ware J. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
31. John M, McKinnon E, James I, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combivir/ abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
32. Hansen A, Lindegaard B, Obel N, et al. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med. 2006;7:38-45.
33. Dube M, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides: dual X-ray absorptiometry results from A5005S, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45:508-514.
34. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials. 2003;4:252-261.
35. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
36. Galli M, Ridolfo A, Fulvio A, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with 2 nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
37. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
38. Snijder M, Dekker J, Visser M, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr. 2003;77:1192-1197.
39. Snijder M, Dekker J, Visser M, et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload levels. Diabetes Care. 2004;27:372-377.
40. Snijder M, Visser M, Dekker J, et al. Low subcutaneous thigh fat is a risk factor for unfavorable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia. 2005;48:301-308.
41. Grunfeld C, Rimland D, Gibert C, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007;46;283-290.
42. Wang J, Kotler D, Russell M, et al. Body-fat measurement in patients with acquired immunodeficiency syndrome: which method should be used? Am J Clin Nutr. 1992;56:963-967.
43. Knox T, Zafonte-Sanders M, Fields-Gardner C, et al. Assessment of nutritional status, body composition, and human immunodeficiency virus-associated morphologic changes. Clin Infect Dis. 2003;36(Suppl 2):S63-S68.
44. He Q, Wang J, Engelson E, et al. Ability of an anthropometric model to track changes in subcutaneous adipose tissue area. FASEB J. 2002;16:A1024-A1025.